Axa’s Inovio Pharmaceuticals INO Stock Holding History

Axa’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,175	Closed	-$243K	–	1270
2016 Q3	$243K	Sell	2,175 -11,461	-84%	-$1.27M	﹤0.01%	1139
2016 Q2	$1.51M	Buy	+13,636	New	+$1.66M	0.01%	792

Other funds holding INO

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axa's INO Position: Q4 2016 in Review

Axa sold out of Inovio Pharmaceuticals (INO) in Q4 2016, closing a stake of 2,175 shares — an estimated $243K sold.

Axa first reported a position in INO in Q2 2016 and held it in 2 quarters. The position peaked at $1.51M in Q2 2016. 125 funds tracked by Wall St. Rank hold INO as of Q4 2016.

Axa reported no remaining Inovio Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Axa sold 2,175 Inovio Pharmaceuticals shares in Q4 2016, an estimated $243K.
Axa first reported a position in Inovio Pharmaceuticals in Q2 2016 and held it in 2 quarters.
Axa's Inovio Pharmaceuticals position peaked at $1.51M in Q2 2016.
125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2016.

Based on Axa's 13F filing for Q4 2016, filed 13 Feb 2017.